Navigation Links
Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
Date:9/21/2007

DANBURY, Conn., Sept. 21 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that the Company has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe. Clinical sites have been initiated in Germany and patient treatment has begun.

"We are expanding VIAject(TM)'s pivotal Phase III trials into Europe to support our planned European registration of VIAject(TM)," stated Dr. Solomon S. Steiner, Chairman and CEO of Biodel. "Given the worldwide prevalence of diabetes, we are determined to establish VIAject(TM) as a global solution. Evaluating VIAject(TM)'s therapeutic profile in European patients with Type 1 and Type 2 diabetes gives us the opportunity to demonstrate VIAject(TM)'s clinical outcomes across a more diverse patient population."

VIAject(TM) is currently undergoing two pivotal Phase III clinical studies. The two studies, one enrolling 400 Type 1 diabetic patients and the other enrolling 400 Type 2 diabetic patients, are comparing the effects of VIAject(TM) to Humulin(R) R, the leading recombinant human insulin. Both studies are open label and involve a treatment regimen that is six months in duration. Clinical endpoints of both trials include non-inferiority in terms of HbA1c levels and safety.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in Phase I clinical trials and tw
'/>"/>

SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
2. PromegaExpress Expands Easy Access to Products with New Cabinet
3. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
4. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
5. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
6. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015  Neurocrine Biosciences, Inc. (NASDAQ: ... has joined the company as Vice President, Medical ... welcome Dr. Bill Aurora to the Neurocrine ... Kevin Gorman , President and Chief Executive Officer of ... exchange and outreach coupled with his extensive network and ...
(Date:5/4/2015)... May 4, 2015  Amgen (NASDAQ: AMGN ) will ... 8 a.m. ET on Thursday, May 7, 2015, at the ... Hooper , executive vice president of Global Commercial Operations at ... presentation can be accessed from the Events Calendar on Amgen,s ... webcast will also be available on Amgen,s website for 90 ...
(Date:5/4/2015)... , May 4, 2015 DePuy Synthes CMF* ... Repair, the first commercially available biosynthesized dural replacement derived ... is a part of the DePuy Synthes Companies of ... tissue membrane that covers and protects the brain and ... to allow surgeons to access the brain. A dural ...
Breaking Medicine Technology:Neurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs 2Neurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs 3Amgen To Present At The Deutsche Bank 40th Annual Healthcare Conference 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3
... YORK, Jan. 10, 2011 Resolvyx Pharmaceuticals ( Resolvyx ... ), a successor firm to Celtic Pharma, announced today ... which Celtic Therapeutics has acquired and licensed worldwide rights ... treatment of dry eye syndrome and other ophthalmic conditions. ...
... 2011 Astellas Pharma Inc. (TSE: 4503) ... to conduct, in conjunction with executive management, a review of ... Prosidion was acquired as part of Astellas, acquisition of OSI ... two drug candidates in development for diabetes and obesity, as ...
Cached Medicine Technology:Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 2Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 3Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 4Astellas to Review Strategic Business Alternatives for Prosidion Subsidiary 2Astellas to Review Strategic Business Alternatives for Prosidion Subsidiary 3
(Date:5/4/2015)... The National Association of Professional Women ... 2015-2016 inductee into the NAPW VIP Woman of the ... for leadership in oral healthcare. NAPW is the nation's ... than 700,000 members and over 200 operating Local Chapters. ... group of professional women," said NAPW President Star Jones. ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Every Friday ... treatment center located in Southwest Michigan, patients and staff ... of those graduating the rehabilitation program and to gain ... their addictions. , One by one, those patients ... podium to accept their certificates and to share a ...
(Date:5/4/2015)... The American Council of Engineering Companies ... of Stanley Consultants , to the Institute ... a three-year term. , ACEC co-established ISI with the ... of Civil Engineers (ASCE). A non-profit group, ISI ... infrastructure called Envision. Launched in 2012, the Envision rating ...
(Date:5/4/2015)... Malibu Biotech Systems LLC salutes the ... is the first personal hygiene product dedicated specifically ... fresh breath appeal. KissSafe™ contains an FDA-approved active ... the mouth and oral cavity before and after ... additional wellness benefits. KissSafe’s proprietary prevent-tech will be ...
(Date:5/4/2015)... May 04, 2015 Leonardo J. Lozada, ... chief physician executive, and William C. Daniel, M.D., Saint ... accepted personal invitations from the Secretary of the Air ... (NSF) at the Air War College, Maxwell Air Force ... influential citizens to senior U.S. and international officers and ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Elizabeth Moncada, Owner, Moncada Center for Orofacial Pain, into its 2015-2016 VIP Woman of the Year Circle 2Health News:A Forever Recovery Celebrates New Victories in Overcoming Addiction With Weekly Graduation 2Health News:Thomopulos Appointed to Institute for Sustainable Infrastructure Board 2Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2
... Superficial vein thrombosis linked to deep vein thrombosis, study ... supposedly harmless condition -- superficial vein thrombosis, or varicose ... herald the presence of a more dangerous problem. , ... an Austrian study actually had deep vein thrombosis (DVT), ...
... still working on H1N1 swine flu vaccine, which should be ... The U.S. Food and Drug Administration has approved the vaccine ... Monday. , The agency noted that this vaccine will not ... reached pandemic proportions around the world and is expected to ...
... has spawned similar efforts across the U.S., report finds, ... New York City Health Department mandated that city restaurants ... be a health hazard, the action was greeted with ... state, comments," said Dr. Lynn Silver, assistant commissioner of ...
... , , NEW YORK, July ... Door" program for patients with multiple myeloma. Cancer Care ,s program will provide ... transportation costs such as gasoline and taxi, bus or train fare to and ... program is funded in part by a generous grant from Millennium: The Takeda ...
... pancreatic research, study suggests , MONDAY, July 20 (HealthDay News) ... an important role in directing cells to become part of ... say this finding could help efforts to find a cure ... that the Sox17 gene "acts like a toggle or binary ...
... , , LOS ANGELES, July 20 ... W. Nahas, managing director of the Southern California region of Korn/Ferry ... organization,s corporate board of directors. The appointment of Nahas marks the ... will replace outgoing board chair, Jeffrey M. Johnson, principal, The Yucaipa ...
Cached Medicine News:Health News:Vein Condition May Mask Serious Clot Disorder 2Health News:FDA Approves Seasonal Flu Vaccine for 2009-2010 2Health News:FDA Approves Seasonal Flu Vaccine for 2009-2010 3Health News:In New York City, Trans Fat Ban Is Working 2Health News:In New York City, Trans Fat Ban Is Working 3Health News:CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 2Health News:CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 3Health News:Cell Discovery May Bring Science Closer to Diabetes Cure 2Health News:Caroline W. Nahas Named New Corporate Board Chair for United Way of Greater Los Angeles 2Health News:Caroline W. Nahas Named New Corporate Board Chair for United Way of Greater Los Angeles 3
... software accurately differentiates clinically significant progression ... variability, providing an advanced, proven method ... your patients. , ,The software applies ... trial, in which the actual test/retest ...
With MediLive MindStream you can make, cut and edit digital videos, add commentaries and notes, and save them. MediLive MindStream - intuitive user interface and high-resolution monitor all in one....
... VISUPAC system and the FF 450plus Fundus ... unique level of accuracy and security that ... aftermarket configuration. Without this level of integrated ... assured.,Matching the VISUPAC system pixel for pixel, ...
... Our revolutionary Decipher Holter Monitor is ... in the industry. Designed with an on-board ... capable of detecting 40 different arrhythmias while ... only Holter Monitor to pass all the ...
Medicine Products: